SCHEMBL3930950

SCHEMBL3930950

CC(C)(C)OC(=O)C1(NCC(=O)O)CCc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.38
HDAC9 Q9UKV0 1/20 0.38
TACR3 P29371 2/20 0.37
TACR1 P25103 1/20 0.37
GHSR Q92847 1/20 0.35
NAMPT P43490 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
RBP4 P02753 1/20 0.34
DRD2 P14416 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926004 0.81 DDB1 (0.43) KDM1AHDAC9TACR3TACR1NR1H2
SCHEMBL4837190 0.76 GHSR (0.43) KDM1AHDAC9GHSRHCAR2DPP8
SCHEMBL18614341 0.76 GHSR (0.43) KDM1AHDAC9GHSRHCAR2DPP8
SCHEMBL306307 0.76 GHSR (0.43) KDM1AHDAC9GHSRHCAR2DPP8
SCHEMBL3940976 0.76 HDAC9 (0.40) HDAC9TACR3TACR1HCAR2
SCHEMBL6931551 0.75 KDM1A (0.37) KDM1AHDAC9HCAR2
SCHEMBL17605147 0.74 AVPR2 (0.39) KDM1AHDAC9TACR3TACR1GHSR
SCHEMBL17605146 0.74 AVPR2 (0.39) KDM1AHDAC9TACR3TACR1GHSR
SCHEMBL5204567 0.74 HDAC9 (0.40) KDM1AHDAC9TACR3TACR1GHSR
SCHEMBL4738908 0.71 GHSR (0.44) KDM1AHDAC9GHSRNAMPTHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541579-B2 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2013-09-24 US disclosed
US-20130131338-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2013-05-23 US disclosed
US-8367673-B2 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2013-02-05 US disclosed
US-20090186867-A1 Substituted Diketopiperazines As Oxytocin Antagonists GLAXO GROUP LIMITED 2009-07-23 US disclosed
US-7514437-B2 Substituted diketopiperazines as oxytocin antagonists SMITHKLINE BEECHAM CORP. (US) 2009-04-07 US disclosed
EP-1458393-B1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LTD (GB) 2008-06-25 EP disclosed
US-20050148572-A1 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2005-07-07 US disclosed
WO-2005000311-A1 SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA GLAXO GROUP LIMITED (GB) 2005-01-06 WO disclosed
EP-1458393-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-09-22 EP disclosed
WO-2003053443-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131338-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS OXTR, AVPR2, CRH KDM1A 4080/4885HDAC9 2100/4885TACR3 281/4885
US-20050148572-A1 Substituted diketopiperazines as oxytocin antagonists OXTR, AVPR2, AVPR1B KDM1A 3948/4885HDAC9 3020/4885TACR3 296/4885
US-20090186867-A1 Substituted Diketopiperazines As Oxytocin Antagonists OXTR, AVPR2, CRH KDM1A 4022/4885HDAC9 2048/4885TACR3 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.